“Our transEDIT-dual CRISPR arrayed library gives researchers a superior set of tools to rapidly identify key therapeutic targets and understand complex biological pathways,” said Blake Simmons, CEO of transOMIC. “We expect the transEDIT-dual CRISPR arrayed library to take our customer’s research further, faster.”
Developed in collaboration with Dr. Greg Hannon of Cold Spring Harbor Laboratory and Cancer Research UK and Dr. Simon Knott of Cedars-Sinai, the transEDIT-dual CRISPR arrayed library uses a new algorithm to create novel and superior gRNA sequences to be used with the CRISPR/Cas9 system. CRISPR/Cas9 is a recently discovered tool for genome editing that has quickly revolutionized the ability to generate site-specific mutations, speeding up the pace of genomic discoveries.
Since 2012, transOMIC has been providing the international scientific community with research products that help unravel genetic complexity and enable insight into gene function, ultimately providing biological understanding of disease and possibilities for therapeutics.
More information about the transEDIT-dual CRISPR arrayed library can be found at http://www.transomic.com/Products/transEdit/transEDIT-dual-CRISPR/Product-Overview.aspx
About transOMIC: transOMIC technologies provides innovative tools and strategies for life science research to help unravel genetic complexity and understand disease development. This mission, coupled with a good understanding of the tools that life science researchers need, drives our focus to be a research partner; delivering technologies in a cost-effective and technically supported manner to enable discovery across the genome. We have an extensive offering of gene-based products to enable research scientists to perform genome editing, gene knockdown, and gene over-expression studies. These types of studies produce insights into gene function which ultimately provide biological understanding of disease and possibilities for therapies. Our leading-edge products are developed through ongoing collaborations with academic thought leaders.
About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological challenges. Opened in 2008, its mission is four-fold: sparking scientific discoveries that can impact human health and well-being; bringing genomic medicine into clinical care; fostering life sciences entrepreneurship and business growth; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus encourage collaborations that produce advances in medicine and agriculture. Under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education, and includes more than 30 diverse biotech companies on campus. To learn more about HudsonAlpha, visit: https://hudsonalpha.org/.